Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection

被引:5
|
作者
Debarry, Jennifer [1 ]
Cornberg, Markus [2 ,3 ]
Manns, Michael P. [1 ,2 ,3 ]
机构
[1] Helmholtz Ctr Infect Res GmbH, Braunschweig, Germany
[2] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[3] German Ctr Infect Res, Partner Site Hannover, Braunschweig, Germany
关键词
access to prophylaxis and treatment; Hepatitis B; linkage to care; screen-and-treat-programs; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; PREVENTION; VACCINATION; DIAGNOSIS; HBSAG; HBV; SEROPREVALENCE; CHEMOTHERAPY; REACTIVATION;
D O I
10.1111/liv.13320
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Despite an available vaccine and efficient treatment for hepatitis B virus (HBV) infection, chronic HBV infection still remains a major global threat, and one of the top 20 causes of human mortality worldwide. One of the major challenges in controlling HBV infection is the high number of undiagnosed chronic carriers and the lack of access to prophylaxis and treatment in several parts of the world. We discuss relevant barriers that need to be overcome to achieve global control of HBV infection and make eradication possible. Most important, vaccination must be scaled-up to lower the risk of vertical transmission and decrease the number of new infections, and comprehensive screening programs must be linked to care to obtain a better rate of diagnosis and treatment. This can probably only be achieved if sustainable funding is available. We therefore emphasize the importance of making the management of viral hepatitis a global health priority.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 50 条
  • [11] Access to Treatment for Hepatitis B Virus Infection - Worldwide, 2016
    Hutin, Yvan
    Nasrullah, Muazzam
    Easterbrook, Philippa
    Nguimfack, Boniface Dongmo
    Burrone, Esteban
    Averhoff, Francisco
    Bulterys, Marc
    [J]. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2018, 67 (28): : 773 - 777
  • [12] Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation
    Shitrit, ABG
    Kramer, MR
    Bakal, I
    Morali, G
    Ben Ari, Z
    Shitrit, D
    [J]. ANNALS OF THORACIC SURGERY, 2006, 81 (05): : 1851 - 1852
  • [14] Hepatitis B Virus Infection in Tanzania: Current Status and Challenges
    Kilonzo, Semvua B.
    Gunda, Daniel W.
    Mpondo, Bonaventura C. T.
    Bakshi, Fatma A.
    Jaka, Hyasinta
    [J]. JOURNAL OF TROPICAL MEDICINE, 2018, 2018
  • [15] Antiviral therapy and resistance with hepatitis B virus infection
    Tillmann, Hans L.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (01) : 125 - 140
  • [16] Antiviral therapy and resistance with hepatitis B virus infection
    Hans L Tillmann
    [J]. World Journal of Gastroenterology, 2007, (01) : 125 - 140
  • [17] Immune therapy of hepatitis B virus chronic infection
    Pol, S
    Michel, ML
    Bréchot, C
    [J]. HEPATOLOGY, 2000, 31 (02) : 548 - 549
  • [18] THERAPY FOR HEPATITIS-B VIRUS-INFECTION
    PERRILLO, RP
    MASON, AL
    [J]. GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1994, 23 (03) : 581 - 601
  • [19] Immunomodulatory therapy for chronic hepatitis B virus infection
    Sprengers, D
    Janssen, HLA
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2005, 19 (01) : 17 - 26
  • [20] Hepatitis B virus infection: Molecular therapy and prevention
    Blum, HE
    vonWeizsacker, F
    Wieland, S
    Offensperger, S
    Offensperger, WB
    Walter, E
    [J]. HEREDITARY CANCER, 1996, : 216 - 228